JPRN-UMIN000019901Completed未知
Impact of esomeprazole and vonoprazan on the antiplatelet effect of clopidogrel and prasugrel, with reference to CYP2C19 genotypes - Impact of PPI on the antipratelet effect of P2Y12 inhibitor
The First Department of Medicine and the Center for Clinical Research at Hamamatsu University School of Medicine0 sites30 target enrollmentStarted: November 24, 2015Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 30
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Exclusion criteria are any underlying disease, smoking habit, past or present H. pylori infection, and habitual use of any medicine.
Investigators
Similar Trials
Recruiting
Not Applicable
COCA studyNL-OMON27946ErasmusMC Cancer Institute22
Active, not recruiting
Phase 1
The effects of the proton pump inhibitor esomeprazole alone or in combination with Coca-Cola on the absorption of Capecitabine in patients with cancer 'the COCA study'Colorectal carcinoma or other solid tumoursEUCTR2017-004465-27-NLErasmus MC Cancer Institute28
Active, not recruiting
Phase 1
The effects of the proton pump inhibitor esomeprazole on the bioavailability of afatinib (Giotrif®) in patients with lung cancer 'the BIO-GIO study'EUCTR2017-001284-20-NLErasmus MC Cancer Institute
Active, not recruiting
Phase 1
The effects of the proton pump inhibitor esomeprazole on the bioavailability of regorafenibEUCTR2015-005784-17-NLErasmus MC cancer institute14
Recruiting
Not Applicable
The effects of the proton pump inhibitor esomeprazole on the bioavailability of afatinib (Giotrif®) in patients with non-small cell lung cancer (NSCLC) 'the BIO-GIO study'NL-OMON45272Erasmus MC, Universitair Medisch Centrum Rotterdam28